Sagara 2018 (Bougoula, Mali).

Study characteristics
Methods	RCT* ‐ represents disaggregated data from Sagara 2018 (see above)
Participants	Number receiving at least 1 study treatment: 619
Interventions	Comparison 1 Pyronaridine‐artesunate (n = 214) Artemether‐lumefantrine (n = 213) Comparison 2 Pyronaridine‐artesunate (n = 94) Amodiaquine‐artesunate (n = 98)
Outcomes	‐
Notes	Location: Bougoula, Mali
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Represents disaggregated data from Sagara 2018 (see above)
Allocation concealment (selection bias)	Low risk	‐
Blinding (performance bias and detection bias) All outcomes	Low risk	‐
Incomplete outcome data (attrition bias) All outcomes	Low risk	‐
Selective reporting (reporting bias)	Low risk	‐
Other bias	Low risk	‐
Adverse event monitoring (detection bias) Adverse events	Low risk	‐
Incomplete adverse event reporting (reporting bias) Adverse events	Low risk	‐